Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 17/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4823243 | 0.74 | CNR1 (0.49) | KDM4EALDH1A1TDP1 | |
| SCHEMBL2494993 | 0.71 | MAPT (0.61) | KDM4EALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL1485752 | 0.68 | MAPT (0.70) | KDM4EL3MBTL1ALDH1A1LMNACYP1A2 | |
| SCHEMBL7470222 | 0.67 | CRHR1 (0.43) | TLR8TLR7ALDH1A1HPGD | |
| SCHEMBL5733104 | 0.67 | TLR9 (0.47) | NPSR1ACP1ALDH1A1LMNAHPGD | |
| SCHEMBL20692502 | 0.66 | MAPT (0.59) | L3MBTL1ALDH1A1 | |
| SCHEMBL17225159 | 0.65 | MAPT (0.57) | L3MBTL1 | |
| SCHEMBL18722580 | 0.65 | MAPT (0.57) | L3MBTL1 | |
| SCHEMBL4823172 | 0.65 | ADORA1 (0.51) | ALDH1A1 | |
| SCHEMBL14516262 | 0.64 | TLR8 (0.47) | TLR8TLR7KDM4EL3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326706-B2 | Pyrazine modulators of cannabinoid receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326706-B2 | Pyrazine modulators of cannabinoid receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326706-B2 | Pyrazine modulators of cannabinoid receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-20050054659-A1 | Pyrazine modulators of cannabinoid receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054659-A1 | Pyrazine modulators of cannabinoid receptors | CNR1, CNR2, GPR18 | TLR8 2723/4885TLR7 1653/4885KDM4E 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.